|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0740 AUD | -2.63% |
|
-8.64% | -12.94% |
| Capitalization | 5.52Cr 3.99Cr 3.4Cr 3.12Cr 2.95Cr 5.47Cr 381.56Cr 37Cr 14Cr 180.98Cr 15Cr 15Cr 628.85Cr | P/E ratio 2024 |
-9.42x | P/E ratio 2025 | -4.7x |
|---|---|---|---|---|---|
| Enterprise value | 5.1Cr 3.68Cr 3.14Cr 2.88Cr 2.73Cr 5.06Cr 352.67Cr 34Cr 13Cr 167.28Cr 14Cr 14Cr 581.24Cr | EV / Sales 2024 |
90.4x | EV / Sales 2025 | 48.5x |
| Free-Float |
79.71% | Yield 2024 * |
-
| Yield 2025 | - |
| 06/25/06 | FDA lifts clinical hold on Nuz-001 | RE |
| 06/25/06 | Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001 | RE |
| 1 day | -2.63% | ||
| 1 week | -8.64% | ||
| Current month | -9.76% | ||
| 1 month | -10.84% | ||
| 3 months | -26.00% | ||
| 6 months | -29.52% | ||
| Current year | -12.94% |
| 1 week | 0.07 |  | 0.08 |
| 1 month | 0.07 | | 0.09 |
| Current year | 0.07 | | 0.1 |
| 1 year | 0.07 | | 0.18 |
| 3 years | 0.06 | | 0.54 |
| 5 years | 0.06 | | 0.54 |
| 10 years | 0.03 | | 0.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Connell
DFI | Director of Finance/CFO | - | 22/04/2025 |
Nicky Wallis
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2024 |
John Clark
CEO | Chief Executive Officer | - | 23/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Marcus Hughes
BRD | Director/Board Member | - | 09/05/2024 |
Sergio Duchini
CHM | Chairman | - | 17/05/2024 |
Michael Thurn
BRD | Director/Board Member | - | 31/05/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.63% | -8.64% | -47.14% | -6.33% | 4.12Cr | |
| +2.35% | +0.01% | +30.89% | +127.65% | 86TCr | |
| +1.43% | -0.07% | +46.23% | +40.19% | 53TCr | |
| +2.39% | +0.85% | +9.36% | +41.26% | 36TCr | |
| +1.82% | -0.38% | +22.40% | +11.63% | 33TCr | |
| +1.82% | +3.14% | +33.84% | +14.47% | 29TCr | |
| +1.93% | +2.08% | +26.42% | +25.26% | 28TCr | |
| +1.37% | -0.10% | +40.54% | -3.50% | 27TCr | |
| -1.17% | +3.71% | -32.83% | -49.56% | 21TCr | |
| +1.56% | +1.77% | +22.08% | +43.99% | 18TCr | |
| Average | +1.05% | -0.58% | +15.18% | +24.51% | 33.09TCr | |
| Weighted average by Cap. | +1.69% | -0.43% | +26.36% | +47.67% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8L 6L 5L 5L 4L 8L 5.82Cr 56.61L 22.04L 2.76Cr 22.8L 22.32L 9.58Cr | 15.38L 11.1L 9L 9L 8L 15.23L 11Cr 1.03Cr 40.27L 5.04Cr 41.66L 40.78L 18Cr |
| Net income | -76.73L -55.39L -47.24L -43.33L -41.01L -76.01L -53Cr -5.16Cr -2.01Cr -25Cr -2.08Cr -2.03Cr -87Cr | -1.66Cr -1.2Cr -1.02Cr -93.7L -88.69L -1.64Cr -114.65Cr -11Cr -4.35Cr -54Cr -4.49Cr -4.4Cr -188.95Cr |
| Net Debt | -1.07Cr -77.46L -66.06L -60.59L -57.35L -1.06Cr -74Cr -7.22Cr -2.81Cr -35Cr -2.91Cr -2.85Cr -122.18Cr | -41.81L -30.18L -25.74L -23.61L -22.35L -41.41L -29Cr -2.81Cr -1.09Cr -14Cr -1.13Cr -1.11Cr -48Cr |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 0.0740 $ | -2.63% | 8,06,561 |
| 11/26/11 | 0.0760 $ | 0.00% | 4,60,871 |
| 08/26/08 | 0.0760 $ | +1.33% | 4,09,096 |
| 07/26/07 | 0.0750 $ | -2.60% | 7,06,379 |
| 06/26/06 | 0.0770 $ | 0.00% | 7,63,543 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0740AUD
Average target price
0.2800AUD
Spread / Average Target
+278.38%
Annual profits - Rate of surprise
- Stock Market
- Equities
- NUZ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition